Steel yourselves for a few days of cardiovascular news aplenty as the American College of Cardiology meeting has kicked off in Orlando. Meanwhile by unpopular demand we must make note of the Australian Grand Prix (heretofore to be referenced as the curious case of Jenson Button). And so long as we're talking about really fast driving we might as well mention some other sporting feats from the weekend: Tiger is Back, Villanova is For Real, and for the upteenth consecutive year this blogger has thrown away multiple hard-earned Alexander Hamiltons on NCAA tourney pools. Oh and Opening Day? Less than a week away.
While you were counting the days ...
- More good news for AZ's Crestor as Jupiter results presented at ACC suggest protection against VTE, too (WSJ).
- Boston Scientific takes on on the chin in the latest stent bout, as its Taxus Liberte stent performed worse than stents from JNJ and Abbott, according to study results presented at ACC (Bloomberg).
- A good place for ACC reportage: EGMN: Notes from the Road. See also: Sheet, The Pink.
- NYT interviews Amgen CEO Kevin Sharer, asks zero questions about Amgen.
- The FIPNET expands as Lilly does a deal with India's Zydus Cadila in the cardiovascular space (Reuters). We told you that nobody escapes the FIPNet. OK, maybe we didn't say exactly that, but still.
- Carl Icahn laments the state of American corporate governance in this NYT Op-Ed. Again with, you guessed it, North Dakota. Man has a good point, no? "If shareholders had enhanced legal rights to elect qualified and responsible board members, it would help our public corporations avoid the kinds of meltdowns we are now experiencing."
image from flickr user StevenM_61 used under a creative commons license.